Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China

Abstract Background While the epidemiologic association between hepatitis B virus (HBV) infection and diffuse large B-cell lymphoma (DLBCL) is established, little known about pathological characteristics outcome of DLBCL arising in patients with HBV infection. Methods We retrospectively studied a cohort 420 for incidence infection, clinicopathologic features prognostic factors HBsAg-positive China, endemic area. Results In our study, 127 (30.2%) were HBsAg-positive. displayed younger median onset age (50 vs. 54 years, P = 0.002), more frequent involvement spleen (19.7% 6.1%, < 0.001), less small intestine (2.3% 11.2%, 0.003), advanced disease (stage III/IV: 56.7% 45.1%, 0.028), lower expression rate MYC (49.1% 66.7%, 0.026). The follow-up time was 61.9 months. Univariate analysis showed that there no significant difference overall survival (OS) HBsAg-negative -positive ( 0.577). subgroup, older than 60 disease, elevated lactate dehydrogenase (LDH), involvement, symptoms (fever, night sweats, weight loss), double expressers BCL2 had significantly worse outcome, treated R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) better prognosis. Multivariate further confirmed rituximab use independent patients. Conclusions Our study indicates has unique clinicopathological factors. Moreover, under antiviral prophylaxis, infections comparable to HBV-negative patients, improved OS